.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Immunotherapy has revolutionized the management of liver cancer. Recent research highlights significant breakthroughs in advanced HCC immunotherapy survival, suggesting that a subset of patients may even achieve a functional cure. By using mixture cure models, researchers can now estimate the proportion of long-term survivors who reach a stable plateau in their survival curves.
Data from pivotal phase 3 trials provide a clearer picture of these outcomes. In the HIMALAYA trial, the combination of durvalumab and tremelimumab resulted in a 12.8% long-term survival rate after five years. This significantly outperformed sorafenib, which showed only 5.2%. Similarly, the RATIONALE-301 trial demonstrated that tislelizumab monotherapy achieved a 25.2% long-term survival rate.
The CheckMate9DW study also offered promising insights into the cure fraction. This trial compared nivolumab-ipilimumab against standard tyrosine kinase inhibitors. The results indicated a cure fraction of 17.8% for the immunotherapy group, while the control group reached only 3.5%. These findings suggest that dual checkpoint inhibition significantly enhances the likelihood of durable remission.
Clinical practice data often differ from controlled trials. However, a large cohort of 1,581 patients treated with atezolizumab-bevacizumab mirrored these trial results. In this real-world setting, long-term survival was 12.3%, and the cure fraction stood at 7.9%.
Identifying which patients will benefit most is crucial. Analysis shows that the ALBI score and the presence of hepatitis C are strong predictors of long-term survival. Additionally, albumin levels and hepatitis C status help clinicians estimate the potential cure fraction. Consequently, these biomarkers allow for more personalized treatment planning in oncology.
A cure fraction refers to the estimated proportion of patients who experience long-term, stable survival without disease progression, effectively reaching a plateau where their mortality risk aligns with the general population.
Combinations like durvalumab-tremelimumab and nivolumab-ipilimumab have demonstrated superior long-term survival and higher cure fractions compared to traditional sorafenib or lenvatinib treatments.
Real-world data for atezolizumab-bevacizumab show a long-term survival rate of approximately 12.3%, which is highly consistent with the 10-15% range observed across various major clinical trials.
Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Evidence from clinical trials and real-world data shows that immunotherapy combinations achieve 10-15% long-term survival and 7-9% cure fractions in advance...
3 months ago
Andhra Pradesh reported 10 new Covid-19 cases, taking the state tally to 49 while deaths remain at four. With 24 patients hospitalized and 16 under home isolation, the Health Department has intensified monitoring. Medical professionals should review regional distribution, diagnostic protocols, and management plans.
Today
An 11-year Swedish registry study of 618 uterine sarcoma patients found that minimally invasive surgery yielded survival comparable to open surgery in early stages. However, adjuvant chemotherapy conferred no survival benefit in localized or advanced disease, highlighting stage and histology as key outcomes.
3 days back
A cross-sectional study evaluates post-intensive care syndrome in cardiac patients 2-4 weeks post-ICU discharge, highlighting cognitive, psychological, and functional impairments and the need for structured multidisciplinary rehabilitation.
3 days back
Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
3 days back
With World Obesity Atlas data warning that over 41 million Indian children are overweight or obese, ICMR and NIN have unveiled a 10-point policy roadmap. The initiative calls for mandatory front-of-pack labeling, HFSS taxes, strict marketing bans, and healthier school environments to curb non-communicable diseases.
Today
